M. Beksac Et Al. , "In the era of Bortezomib-based Induction, intensification of Melphalan-based conditioning with Bortezomib does not improve Survival Outcomes in newly diagnosed Multiple Myeloma: a study from the Chronic Malignancies Working Party of the EBMT," BONE MARROW TRANSPLANTATION , vol.59, no.4, pp.526-533, 2024
Beksac, M. Et Al. 2024. In the era of Bortezomib-based Induction, intensification of Melphalan-based conditioning with Bortezomib does not improve Survival Outcomes in newly diagnosed Multiple Myeloma: a study from the Chronic Malignancies Working Party of the EBMT. BONE MARROW TRANSPLANTATION , vol.59, no.4 , 526-533.
Beksac, M., Eikema, D., Koster, L., Hulin, C., Poire, X., Hamladji, R., ... Gromek, T.(2024). In the era of Bortezomib-based Induction, intensification of Melphalan-based conditioning with Bortezomib does not improve Survival Outcomes in newly diagnosed Multiple Myeloma: a study from the Chronic Malignancies Working Party of the EBMT. BONE MARROW TRANSPLANTATION , vol.59, no.4, 526-533.
Beksac, Meral Et Al. "In the era of Bortezomib-based Induction, intensification of Melphalan-based conditioning with Bortezomib does not improve Survival Outcomes in newly diagnosed Multiple Myeloma: a study from the Chronic Malignancies Working Party of the EBMT," BONE MARROW TRANSPLANTATION , vol.59, no.4, 526-533, 2024
Beksac, Meral Et Al. "In the era of Bortezomib-based Induction, intensification of Melphalan-based conditioning with Bortezomib does not improve Survival Outcomes in newly diagnosed Multiple Myeloma: a study from the Chronic Malignancies Working Party of the EBMT." BONE MARROW TRANSPLANTATION , vol.59, no.4, pp.526-533, 2024
Beksac, M. Et Al. (2024) . "In the era of Bortezomib-based Induction, intensification of Melphalan-based conditioning with Bortezomib does not improve Survival Outcomes in newly diagnosed Multiple Myeloma: a study from the Chronic Malignancies Working Party of the EBMT." BONE MARROW TRANSPLANTATION , vol.59, no.4, pp.526-533.
@article{article, author={Meral Beksac Et Al. }, title={In the era of Bortezomib-based Induction, intensification of Melphalan-based conditioning with Bortezomib does not improve Survival Outcomes in newly diagnosed Multiple Myeloma: a study from the Chronic Malignancies Working Party of the EBMT}, journal={BONE MARROW TRANSPLANTATION}, year=2024, pages={526-533} }